PubMed:26615423 / 1128-1477 JSONTXT

{"project":"LitCoin-sentences","denotations":[{"id":"T9","span":{"begin":0,"end":349},"obj":"Sentence"}],"text":"In the 213 EOC samples, CEP55 protein levels were positively correlated with clinical stage (P \u003c 0.001), lymph node metastasis (P \u003c 0.001), intraperitoneal metastasis (P \u003c 0.001), tumor recurrence (P \u003c 0.001), differentiation grade (P \u003c 0.001), residual tumor size (P \u003c 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P \u003c 0.001)."}

{"project":"LitCoin-entities","denotations":[{"id":"10939","span":{"begin":11,"end":14},"obj":"DiseaseOrPhenotypicFeature"},{"id":"10940","span":{"begin":24,"end":29},"obj":"GeneOrGeneProduct"},{"id":"10941","span":{"begin":105,"end":126},"obj":"DiseaseOrPhenotypicFeature"},{"id":"10942","span":{"begin":140,"end":166},"obj":"DiseaseOrPhenotypicFeature"},{"id":"10943","span":{"begin":180,"end":185},"obj":"DiseaseOrPhenotypicFeature"},{"id":"10944","span":{"begin":254,"end":259},"obj":"DiseaseOrPhenotypicFeature"},{"id":"10945","span":{"begin":278,"end":285},"obj":"DiseaseOrPhenotypicFeature"},{"id":"10946","span":{"begin":290,"end":295},"obj":"DiseaseOrPhenotypicFeature"},{"id":"10947","span":{"begin":325,"end":330},"obj":"GeneOrGeneProduct"}],"attributes":[{"id":"A21","pred":"db_id","subj":"10939","obj":"MESH:D000077216"},{"id":"A22","pred":"db_id","subj":"10940","obj":"NCBIGene:55165"},{"id":"A23","pred":"db_id","subj":"10941","obj":"MESH:D008207"},{"id":"A24","pred":"db_id","subj":"10942","obj":"MESH:D009362"},{"id":"A25","pred":"db_id","subj":"10943","obj":"MESH:D009369"},{"id":"A26","pred":"db_id","subj":"10944","obj":"MESH:D009369"},{"id":"A27","pred":"db_id","subj":"10945","obj":"MESH:D001201"},{"id":"A28","pred":"db_id","subj":"10946","obj":"MESH:D009369"},{"id":"A29","pred":"db_id","subj":"10947","obj":"NCBIGene:4582"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"In the 213 EOC samples, CEP55 protein levels were positively correlated with clinical stage (P \u003c 0.001), lymph node metastasis (P \u003c 0.001), intraperitoneal metastasis (P \u003c 0.001), tumor recurrence (P \u003c 0.001), differentiation grade (P \u003c 0.001), residual tumor size (P \u003c 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P \u003c 0.001)."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T20","span":{"begin":24,"end":29},"obj":"GeneOrGeneProduct"},{"id":"T21","span":{"begin":30,"end":37},"obj":"GeneOrGeneProduct"}],"text":"In the 213 EOC samples, CEP55 protein levels were positively correlated with clinical stage (P \u003c 0.001), lymph node metastasis (P \u003c 0.001), intraperitoneal metastasis (P \u003c 0.001), tumor recurrence (P \u003c 0.001), differentiation grade (P \u003c 0.001), residual tumor size (P \u003c 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P \u003c 0.001)."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T25","span":{"begin":24,"end":29},"obj":"GeneOrGeneProduct"},{"id":"T26","span":{"begin":30,"end":37},"obj":"GeneOrGeneProduct"},{"id":"T27","span":{"begin":105,"end":110},"obj":"GeneOrGeneProduct"},{"id":"T28","span":{"begin":111,"end":115},"obj":"GeneOrGeneProduct"},{"id":"T29","span":{"begin":180,"end":185},"obj":"GeneOrGeneProduct"},{"id":"T30","span":{"begin":254,"end":259},"obj":"GeneOrGeneProduct"},{"id":"T31","span":{"begin":260,"end":264},"obj":"GeneOrGeneProduct"},{"id":"T32","span":{"begin":290,"end":295},"obj":"GeneOrGeneProduct"},{"id":"T33","span":{"begin":296,"end":301},"obj":"GeneOrGeneProduct"},{"id":"T34","span":{"begin":325,"end":330},"obj":"GeneOrGeneProduct"}],"text":"In the 213 EOC samples, CEP55 protein levels were positively correlated with clinical stage (P \u003c 0.001), lymph node metastasis (P \u003c 0.001), intraperitoneal metastasis (P \u003c 0.001), tumor recurrence (P \u003c 0.001), differentiation grade (P \u003c 0.001), residual tumor size (P \u003c 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P \u003c 0.001)."}

{"project":"LitCoin-Disease-MeSH","denotations":[{"id":"T10","span":{"begin":11,"end":14},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T11","span":{"begin":105,"end":126},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T12","span":{"begin":156,"end":166},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T13","span":{"begin":180,"end":185},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T14","span":{"begin":186,"end":196},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T15","span":{"begin":245,"end":259},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T16","span":{"begin":278,"end":285},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T17","span":{"begin":290,"end":295},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A13","pred":"originalLabel","subj":"T13","obj":"D009369"},{"id":"A15","pred":"originalLabel","subj":"T15","obj":"D018365"},{"id":"A12","pred":"originalLabel","subj":"T12","obj":"D009362"},{"id":"A10","pred":"originalLabel","subj":"T10","obj":"D000077216"},{"id":"A17","pred":"originalLabel","subj":"T17","obj":"D009369"},{"id":"A16","pred":"originalLabel","subj":"T16","obj":"D001201"},{"id":"A11","pred":"originalLabel","subj":"T11","obj":"D008207"},{"id":"A14","pred":"originalLabel","subj":"T14","obj":"D012008"}],"text":"In the 213 EOC samples, CEP55 protein levels were positively correlated with clinical stage (P \u003c 0.001), lymph node metastasis (P \u003c 0.001), intraperitoneal metastasis (P \u003c 0.001), tumor recurrence (P \u003c 0.001), differentiation grade (P \u003c 0.001), residual tumor size (P \u003c 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P \u003c 0.001)."}

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T12","span":{"begin":24,"end":29},"obj":"GeneOrGeneProduct"}],"text":"In the 213 EOC samples, CEP55 protein levels were positively correlated with clinical stage (P \u003c 0.001), lymph node metastasis (P \u003c 0.001), intraperitoneal metastasis (P \u003c 0.001), tumor recurrence (P \u003c 0.001), differentiation grade (P \u003c 0.001), residual tumor size (P \u003c 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P \u003c 0.001)."}

{"project":"LitCoin_Mondo_095","denotations":[{"id":"T7","span":{"begin":180,"end":185},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":254,"end":259},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":290,"end":295},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A7","pred":"mondo_id","subj":"T7","obj":"0005070"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"0005070"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"0005070"}],"text":"In the 213 EOC samples, CEP55 protein levels were positively correlated with clinical stage (P \u003c 0.001), lymph node metastasis (P \u003c 0.001), intraperitoneal metastasis (P \u003c 0.001), tumor recurrence (P \u003c 0.001), differentiation grade (P \u003c 0.001), residual tumor size (P \u003c 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P \u003c 0.001)."}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T10","span":{"begin":11,"end":14},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T11","span":{"begin":105,"end":126},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T12","span":{"begin":156,"end":166},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T13","span":{"begin":180,"end":185},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T14","span":{"begin":186,"end":196},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T15","span":{"begin":245,"end":259},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T16","span":{"begin":278,"end":285},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T17","span":{"begin":290,"end":295},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A17","pred":"ID:","subj":"T17","obj":"D009369"},{"id":"A12","pred":"ID:","subj":"T12","obj":"D009362"},{"id":"A11","pred":"ID:","subj":"T11","obj":"D008207"},{"id":"A16","pred":"ID:","subj":"T16","obj":"D001201"},{"id":"A13","pred":"ID:","subj":"T13","obj":"D009369"},{"id":"A14","pred":"ID:","subj":"T14","obj":"D012008"},{"id":"A15","pred":"ID:","subj":"T15","obj":"D018365"},{"id":"A10","pred":"ID:","subj":"T10","obj":"D000077216"}],"text":"In the 213 EOC samples, CEP55 protein levels were positively correlated with clinical stage (P \u003c 0.001), lymph node metastasis (P \u003c 0.001), intraperitoneal metastasis (P \u003c 0.001), tumor recurrence (P \u003c 0.001), differentiation grade (P \u003c 0.001), residual tumor size (P \u003c 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P \u003c 0.001)."}

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T8","span":{"begin":11,"end":14},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":105,"end":126},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T10","span":{"begin":180,"end":185},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T11","span":{"begin":245,"end":259},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T12","span":{"begin":278,"end":285},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T13","span":{"begin":290,"end":295},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A8","pred":"#label","subj":"T8","obj":"D000077216"},{"id":"A9","pred":"#label","subj":"T9","obj":"D008207"},{"id":"A10","pred":"#label","subj":"T10","obj":"D009369"},{"id":"A11","pred":"#label","subj":"T11","obj":"D018365"},{"id":"A12","pred":"#label","subj":"T12","obj":"D001201"},{"id":"A13","pred":"#label","subj":"T13","obj":"D009369"}],"text":"In the 213 EOC samples, CEP55 protein levels were positively correlated with clinical stage (P \u003c 0.001), lymph node metastasis (P \u003c 0.001), intraperitoneal metastasis (P \u003c 0.001), tumor recurrence (P \u003c 0.001), differentiation grade (P \u003c 0.001), residual tumor size (P \u003c 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P \u003c 0.001)."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T12","span":{"begin":24,"end":29},"obj":"GeneOrGeneProduct"},{"id":"T3276","span":{"begin":290,"end":295},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T66686","span":{"begin":278,"end":285},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T27874","span":{"begin":245,"end":259},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T24130","span":{"begin":180,"end":185},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T62122","span":{"begin":105,"end":126},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T52084","span":{"begin":11,"end":14},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A13","pred":"#label","subj":"T3276","obj":"D009369"},{"id":"A12","pred":"#label","subj":"T66686","obj":"D001201"},{"id":"A11","pred":"#label","subj":"T27874","obj":"D018365"},{"id":"A10","pred":"#label","subj":"T24130","obj":"D009369"},{"id":"A9","pred":"#label","subj":"T62122","obj":"D008207"},{"id":"A8","pred":"#label","subj":"T52084","obj":"D000077216"}],"text":"In the 213 EOC samples, CEP55 protein levels were positively correlated with clinical stage (P \u003c 0.001), lymph node metastasis (P \u003c 0.001), intraperitoneal metastasis (P \u003c 0.001), tumor recurrence (P \u003c 0.001), differentiation grade (P \u003c 0.001), residual tumor size (P \u003c 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P \u003c 0.001)."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"26615423-8#24#29#gene55165","span":{"begin":24,"end":29},"obj":"gene55165"},{"id":"26615423-8#156#166#diseaseC0027627","span":{"begin":156,"end":166},"obj":"diseaseC0027627"},{"id":"26615423-8#105#126#diseaseC0686619","span":{"begin":105,"end":126},"obj":"diseaseC0686619"},{"id":"26615423-8#180#196#diseaseC0521158","span":{"begin":180,"end":196},"obj":"diseaseC0521158"}],"relations":[{"id":"24#29#gene55165156#166#diseaseC0027627","pred":"associated_with","subj":"26615423-8#24#29#gene55165","obj":"26615423-8#156#166#diseaseC0027627"},{"id":"24#29#gene55165105#126#diseaseC0686619","pred":"associated_with","subj":"26615423-8#24#29#gene55165","obj":"26615423-8#105#126#diseaseC0686619"},{"id":"24#29#gene55165180#196#diseaseC0521158","pred":"associated_with","subj":"26615423-8#24#29#gene55165","obj":"26615423-8#180#196#diseaseC0521158"}],"text":"In the 213 EOC samples, CEP55 protein levels were positively correlated with clinical stage (P \u003c 0.001), lymph node metastasis (P \u003c 0.001), intraperitoneal metastasis (P \u003c 0.001), tumor recurrence (P \u003c 0.001), differentiation grade (P \u003c 0.001), residual tumor size (P \u003c 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P \u003c 0.001)."}